186 related articles for article (PubMed ID: 37382251)
1. Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review.
Mumtaz H; Nadeem A; Bilal W; Ansar F; Saleem S; Khan QA; Tango T; Farkouh C; Belay NF; Verma R; Farkouh M; Saqib M
Immun Inflamm Dis; 2023 Jun; 11(6):e899. PubMed ID: 37382251
[TBL] [Abstract][Full Text] [Related]
2. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
[TBL] [Abstract][Full Text] [Related]
3. Feasibility, safety, and impact of the RTS,S/AS01
Asante KP; Mathanga DP; Milligan P; Akech S; Oduro A; Mwapasa V; Moore KA; Kwambai TK; Hamel MJ; Gyan T; Westercamp N; Kapito-Tembo A; Njuguna P; Ansong D; Kariuki S; Mvalo T; Snell P; Schellenberg D; Welega P; Otieno L; Chimala A; Afari EA; Bejon P; Maleta K; Agbenyega T; Snow RW; Zulu M; Chinkhumba J; Samuels AM;
Lancet; 2024 Apr; 403(10437):1660-1670. PubMed ID: 38583454
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
[TBL] [Abstract][Full Text] [Related]
5. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
7. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
[TBL] [Abstract][Full Text] [Related]
8. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
Vandoolaeghe P; Schuerman L
Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
[TBL] [Abstract][Full Text] [Related]
9. "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana.
Darkwa S; de Wildt G; Dalaba M; Vidzro E; Ansah EK
PLoS One; 2022; 17(6):e0268009. PubMed ID: 35675273
[TBL] [Abstract][Full Text] [Related]
10. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review.
Dimala CA; Kika BT; Kadia BM; Blencowe H
PLoS One; 2018; 13(12):e0209744. PubMed ID: 30596732
[TBL] [Abstract][Full Text] [Related]
11. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
[TBL] [Abstract][Full Text] [Related]
12. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
[TBL] [Abstract][Full Text] [Related]
13. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
14. Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective.
Hill J; Bange T; Hoyt J; Kariuki S; Jalloh MF; Webster J; Okello G
Lancet Glob Health; 2024 Apr; 12(4):e672-e684. PubMed ID: 38430916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of RTS,S/AS01
Samuels AM; Ansong D; Kariuki SK; Adjei S; Bollaerts A; Ockenhouse C; Westercamp N; Lee CK; Schuerman L; Bii DK; Osei-Tutu L; Oneko M; Lievens M; Attobrah Sarfo MA; Atieno C; Morelle D; Bakari A; Sang T; Jongert E; Kotoh-Mortty MF; Otieno K; Roman F; Buabeng PBY; Ntiamoah Y; Ofori-Anyinam O; Agbenyega T;
Lancet Infect Dis; 2022 Sep; 22(9):1329-1342. PubMed ID: 35753316
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
17. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
18. Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.
Moturi AK; Jalang'o R; Cherono A; Muchiri SK; Snow RW; Okiro EA
Malar J; 2023 Sep; 22(1):287. PubMed ID: 37759277
[TBL] [Abstract][Full Text] [Related]
19. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
Merle CS;
Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716
[TBL] [Abstract][Full Text] [Related]
20. [Vaccination against malaria].
Mura M
Med Trop Sante Int; 2023 Jun; 3(2):. PubMed ID: 37525687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]